Sartorius sets up Life Science Factory for startup entrepreneurs
Life Science Factory gGmbH offers labs, co-working spaces and consulting services for life science entrepreneurs.
With its newly founded, independent Life Science Factory, Sartorius intends to promote startups and attract entrepreneurs from the life science sector.
Life Science Factory offers space and support to prospective scientific entrepreneurs and young companies willing to take their first steps beyond the comfort zone of academic institutions. Based on an exemplary business model already established in the US as a launch pad for life science startups, the Life Science Factory strategy provides for the interaction of lab areas, coworking rooms and network offerings, such as mentoring and company financing. The firm’s professional operating concept ensures efficient facility management and administrative support, high-quality laboratory equipment and qualified lab staff.
“In this combination, such an approach is new in Germany and other European countries,” comments Sartorius Executive Board Chairman and CEO Joachim Kreuzburg. “Life science startups primarily lack suitable lab facilities and a powerful network, apart from access to startup and growth capital. Flexible and open-design spaces for labs, offices and events are a good breeding ground for trying out new things and sharing contacts and experiences with like-minded peers and veteran founders.“ He says that Life Science Factory is intended to propel Göttingen beyond its reputation focusing on scientific expertise, establishing the city as a genuine hotspot for life science startups. The managing directors of Life Science Factory gGmbH, a non-profit, are entrepreneur and founder Marco Janezic and Sven Wagner, who heads the Business Development unit at Sartorius and had previously worked at two life science startups.
Life Science Factory will work closely with local partners, such as Göttingen’s universities, MaxPlanck institutes and the Southern Lower Saxony Innovation Campus, SNIC, and, beyond these, with its wider network. For example, the non-profit will be the venue for startup activities of the Fraunhofer-Gesellschaft, Europe’s largest application-oriented research organization, such as Fraunhofer Life Science Days, or for the initiative of the Young Entrepreneurs in Science of the Falling Walls Foundation. “Göttingen has the potential and the opportunity to achieve a much stronger position in this extremely dynamic and socially important field than has been the case so far,” says Kreuzburg.
The non-profit will be ready to start off in early 2019: Office space in the inner city of Göttingen will be available on more than 500 m2 for co-working, experiments and events, and can be rented by entrepreneurs for working and prototype building. The offices will also offer the latest equipment, such as 3-D printers and laser cutters. In addition, lectures to be held by patent attorneys or successful startup founders, for instance, are scheduled as are further events addressing startup issues. Any earnings generated by Life Science Factory will be reinvested in the promotion of knowledge transfer and of young scientists and researchers.
In 2021, Life Science Factory plans to move to the new Sartorius Quarter. Providing a total area of more than 3,000 square meters, the new facility for Life Science Factory will be one of the first buildings to open in the new city quarter at the previous Sartorius site. “Our former company headquarters was always a place of taking entrepreneurial initiative and of turning science into practical industrial solutions, especially in life sciences. For this reason, the Sartorius Quarter is also designed to continue as a place for ideas and innovations in the future as well. Through this Life Science Factory, our company is upholding its long-term commitment to this location and thus to also close a gap in Göttingen,” says Kreuzburg. At the end of 2017, Sartorius relocated its headquarters after operating for some 120 years at its traditional site in the inner city of Göttingen to Sartorius Campus in the Göttingen-Grone industrial zone.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance